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Abstract
Aims/hypothesis Hypomagnesaemia (blood Mg2+ <0.7 mmol/l) is a common phenomenon in individuals with type 2 diabetes.
However, it remains unknown how a low blood Mg2+ concentration affects lipid and energy metabolism. Therefore, the
importance of Mg2+ in obesity and type 2 diabetes has been largely neglected to date. This study aims to determine the effects
of hypomagnesaemia on energy homeostasis and lipid metabolism.
Methods Mice (n = 12/group) were fed either a low-fat diet (LFD) or a high-fat diet (HFD) (10% or 60% of total energy) in
combination with a normal- or low-Mg2+ content (0.21% or 0.03%wt/wt) for 17 weeks.Metabolic cages were used to investigate
food intake, energy expenditure and respiration. Blood and tissues were taken to study metabolic parameters and mRNA
expression profiles, respectively.
Results We show that low dietary Mg2+ intake ameliorates HFD-induced obesity in mice (47.00 ± 1.53 g vs 38.62 ± 1.51 g in
mice given a normal Mg2+-HFD and low Mg2+-HFD, respectively, p < 0.05). Consequently, fasting serum glucose levels
decreased and insulin sensitivity improved in low Mg2+-HFD-fed mice. Moreover, HFD-induced liver steatosis was absent in
the lowMg2+ group. In hypomagnesaemic HFD-fed mice, mRNA expression of key lipolysis genes was increased in epididymal
white adipose tissue (eWAT), corresponding to reduced lipid storage and high blood lipid levels. Low Mg2+-HFD-fed mice had
increased brown adipose tissue (BAT) Ucp1 mRNA expression and a higher body temperature. No difference was observed in
energy expenditure between the two HFD groups.
Conclusions/interpretation Mg2+-deficiency abrogates HFD-induced obesity in mice through enhanced eWAT lipolysis and
BAT activity.
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Abbreviations
BAT Brown adipose tissue
eWAT Epididymal white adipose tissue
HFD High-fat diet
GO Gene ontology
iWAT Inguinal white adipose tissue
LFD Low-fat diet
LowMg Low Mg2+ (diet)
NormMg Normal Mg2+ (diet)
RER Respiratory exchange ratio
WAT White adipose tissue
Introduction
Hypomagnesaemia (blood Mg2+ concentration <0.7 mmol/l) af-
fects approximately 30% of individuals with type 2 diabetes [1,
2]. Hypomagnesaemia is an important risk factor for the devel-
opment and progression of type 2 diabetes [3–5]. Low dietary
Mg2+ intake and reduced serum Mg2+ concentrations have also
been associatedwith obesity, althoughwith conflicting results [1,
6–8].Moreover, reduced bloodMg2+ levels have been correlated
with elevated glucose and triacylglycerol concentrations in indi-
viduals with type 2 diabetes, suggesting that hypomagnesaemia
is associated with insulin resistance and dyslipidaemia [1].
Mg2+ fulfils many roles including cell growth, membrane
stability, enzyme activity and energy metabolism [9]. It is a
cofactor for numerous enzymes, primarily because it stabilises
ATP and facilitates phosphate transfer reactions [10, 11]. Mg2+
is essential for glycolysis and the citric acid cycle [12, 13].
Because Mg2+ is critical for insulin receptor tyrosine kinase
activity, hypomagnesaemia has also been implicated in insulin
resistance [14–16]. Recently, hypomagnesaemia in mice was
shown to contribute to enhanced catabolism, but no in-depth
metabolic phenotype analysis was performed [17].
In type 2 diabetes, restoring serum Mg2+ values by oral
Mg2+ supplementation improves insulin sensitivity, decreases
fasting glucose levels [18] and corrects the lipid profile
[19–21]. Although Mg2+ is essential for key enzymes in lipid
metabolism, including hepatic lipase and lecithin-cholesterol
acyltransferase [22, 23], the effects of chronic Mg2+ deficien-
cy on adipocyte function and lipid metabolism remain largely
unknown.
In this study, we explored the role of Mg2+ in energy ho-
meostasis, insulin sensitivity and lipid metabolism, by feeding
mice a low-fat diet (LFD) or a high-fat diet (HFD) combined
with low or normal Mg2+ for 17 weeks. The resulting meta-
bolic effects were extensively characterised. Data were con-
firmed by an independent replication experiment.
Methods
Seventeen-week mouse study: Radboud university medical
center This study was approved by the animal ethics board of
the Radboud University Nijmegen (RU DEC 2015-0073) and
the Dutch Central Commission for Animal Experiments (CCD,
AVD103002015239). Forty-eight male C57BL6/J mice
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(Charles River Laboratories, Sulzfeld, Germany), aged 9–
10 weeks, were randomly allocated to four experimental
groups of n = 12 mice. Experimental diets consisted of 10%
or 60% energy from palm oil plus 0.03% or 0.21% wt/wt mag-
nesium oxide. Researchers and animal caretakers were blinded
for Mg2+ content. On days −1, 84 and 112, mice were housed
individually in metabolic cages for 24 h. Blood was collected
via cheek puncture at days −1, 28, 56 and 84. At weeks 14 and
15, ITTandGTT, respectively, were performed. After 17weeks
on the diets, mice were anaesthetised by 4% vol./vol. isoflurane
and exsanguinated via orbital sinus bleeding. See electronic
supplementary material (ESM) for full methods.
Intraperitoneal insulin and glucose tolerance tests After
14 weeks on the diets, mice underwent an intraperitoneal
ITT. After 6 h of fasting, from 08:00 to 14:00, mice were
injected with 0.75 U/kg body weight of human insulin
(Novorapid, Novo Nordisk, Bagsværd, Denmark). Blood glu-
cose levels were measured at 0, 20, 40, 60, 90 and 120 min.
After 15 weeks on the diets, mice underwent an IPGTT. After
an overnight fast, from 18:00 to 09:00, mice were injected
with 2 g/kg body weight of D-glucose (Invitrogen, Bleiswijk,
the Netherlands). Blood glucose was measured at 0, 15, 30, 60
and 120 min. See ESM for full methods.
Quantitative real-time PCR Total RNA was extracted using
TRIzol reagent (Invitrogen, Paisley, UK), subjected to
DNase (Promega, Fitchburg, WI, USA) treatment and mea-
sured using the Nanodrop 2000c spectrophotometer (Thermo
Scientific,Waltham,MA,USA). RNAwas reverse transcribed
using Moloney murine leukaemia virus (M-MLV) reverse
transcriptase (Invitrogen, Bleiswijk, the Netherlands). Gene
expression levels were quantified by SYBR-Green (Bio-
Rad, Veenendaal, the Netherlands) on a CFX96 real-time
PCR detection system (Bio-Rad) and normalised for Gapdh.
Primer sequences for Acadl, Adrb3, Atgl (also known as
Pnpla2), Cact, Cd36, Cpt1-l (also known as Cpt1a), Cpt1-m
(also known as Cpt1b), Cpt2, Fbp1, G6pase (also known as
G6pc), Gapdh, Glut1 (also known as Slc2a1), Glut2 (also
known as Slc2a2), Glut4 (also known as Slc2a4), Gs, Gyk,
Hmgcs1, Hsl (also known as Lipe), Mgll, Pepck1, Pklr,
Ppar-α (also known as Ppara), Ppar-γ (also known as
Pparg), Srebp1 (also known as Srebf1) andUcp1 are provided
in ESM Table 1.
Histology Epididymal fat and liver tissues were fixed in 10%
vol./vol. neutral-buffered formalin (KLINIPATH, Duiven, the
Netherlands) in PBS. Samples were dehydrated through alco-
hol, embedded in paraffin and cut into 4 μm sections. Sections
were stained with H&E using standard procedures. The ave-
rage cell size of 100–300 cells per mouse was determined
manually using ImageJ software (v1.48, NIH, Bethesda,
MD, USA, RRID:SCR_003070). Liver samples were snap
frozen in liquid nitrogen, cut into 10 μm sections, stained with
Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) and coun-
terstained with haematoxylin.
RNA sequencing Five randomly selected samples of each
group were analysed, with no technical replicates, by RNA
sequencing. Quality control and RNA sequencing were per-
formed by the Beijing Genomics Institute (BGI), Hong Kong,
China. Per sample, 13 million reads were sequenced using the
Hiseq 4000 platform (Illumina, San Diego, CA, USA) using a
50 bp single-end module. Clean reads were mapped to Mus
musculus transcriptome (GRCm38/mm10) using the HISAT/
Bowtie2 tool (RRID:SCR_005476) [24, 25]. RSEM software
v1.2.31 (RRID:SCR_013027) was used to quantify gene ex-
pression levels (fragments per kilobase million [FPKM]
values) [26]. FPKM values were log2 transformed and further
analysed in R (www.r-project.org, v3.4.1., RRID:SCR_
001905). Heatmaps for individual GO terms were created
using the ggplot2 library (r-project) [27]. See ESM for full
method details.
Analytical procedures Serum Mg2+ was determined using a
spectrophotometric assay at 600 nm (Roche/Hitachi, Tokyo,
Japan) according to the manufacturer’s protocol. Liver sam-
ples were weighed and lysed in lysis buffer (10% wt/vol.)
containing 50 mmol/l Tris-HCl pH 7.5, 1 mmol/l EGTA,
1 mmol/l EDTA, 1% vol./vol. Triton X-100, 10 mmol/l glyc-
erophosphate, 1 mmol/l sodium orthovanadate, 50 mmol/l so-
dium fluoride, 10 mmol/l sodium pyrophosphate and
150 mmol/l sodium chloride. Triacylglycerol concentrations
in serum and liver lysate were assayed using an enzymatic kit
(Roche Molecular Biochemicals, Indianapolis, IN, USA), ac-
cording to the manufacturer’s protocol. Serum NEFA (NEFA-
C kit, WAKO Diagnostics, Delfzijl, the Netherlands), choles-
terol (Human Diagnostics, Wiesbaden, Germany), glucose
(Instruchemie, Delfzijl, the Netherlands), leptin (R&D
Systems, Minneapolis, MN, USA) and adiponectin (R&D
Systems, Minneapolis, MN, USA) concentrations were deter-
mined according to manufacturers’ protocols.
3-Methoxytyramine and normetanephrinewere analysed by a
6490 LC-MS/MS (Agilent Technologies, Amstelveen, the
Netherlands) after solid phase extraction (SPE) Oasis WCX
μElution sample cleanup (Waters, Etten-Leur, the Netherlands).
A calibration curve was used with 3-methoxytyramine-HCl and
normetanephrine-HCl (Sigma-Aldrich, St. Louis, MO, USA) as
calibrators. 3-Methoxytyramine-d4-HCl and normetanephrine-
d3-HCl (Medical Isotopes, Pelham, NH, USA) were used as
internal standards. An ethylene bridged hybrid (BEH) Amide
1.7 μm 100A, 2.1 × 100 mm column (Waters) was used as an
analytical column.
Nine-week replication mouse study: MRC Harwell Institute
All experimental procedures were conducted in compliance
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with the UK Animals Scientific Procedures Act (1986) and
University of Oxford ethical guidelines. Thirty-nine male
C57BL6/J mice (Medical Research Council [MRC],
Harwell, UK) were randomly allocated to four groups of n =
10 mice (n = 9 in the low Mg2+[LowMg]-LFD group). At
8 weeks old, mice were put on experimental diets identical
to the Radboud university medical center experiment for
9 weeks. At day 14, mice were housed individually in meta-
bolic cages (Tecniplast, Buguggiate, Italy). Blood was collec-
ted via tail bleed at days −1 and 14. Respiration metabolic
cages (TSE PhenoMaster Cages, Bad Homburg, Germany)
were used at days 28 and 56 and body temperatures were
measured by rectal probe (ATP-instrumentation, Ashby,
UK). Data were averaged per hour and plotted from 18:30 to
09:30 h. See ESM Methods for full details.
Lipolysis in 3 T3-L1 adipocytes Differentiated 3 T3-L1 cells
(mycoplasma-free, ATCC,Manassas, VA, USA) were incuba-
ted for 20 h in DMEM, containing 0 or 1 mmol/l MgCl2.
Aliquots of 50 μl medium were taken hourly and heated for
8 min at 65°C. The concentration of NEFAwas assessed using
the WAKO NEFA-C kit (Instruchemie, Delfzijl, the
Netherlands). See ESM Methods for full details.
Statistics For the animal experiments, a two-way ANOVAwas
used to look for a significant interaction effect between the
twomain variables (dietary fat andMg2+ content). If there was
none, significant differences between the groups were
assessed using a two-way ANOVA approach with a Tukey’s
multiple comparisons test. If the two-way ANOVA demon-
strated a significant interaction effect between the two main
variables, an unpaired multiple t test approach using the
Holm–Sidak method for multiple comparisons was used.
Statistical significance was determined using Graphpad
Prism v7 (La Jolla, CA, USA, RRID: SCR_002798). For the
lipolysis assays, an unpaired Student’s t test was used.
Differences with a p value of <0.05 were considered statis-
tically significant. Results are presented as mean ± SEM.
Results
Low dietary Mg2+ intake reduces diet-induced obesity in mice
The mice were fed an LFD or HFD containing either a low
(0.03% wt/wt) or normal (0.21% wt/wt) Mg2+ concentration
for 17 weeks (Fig. 1a). There was no difference in body
weight between low and normal Mg2+ groups on the LFD,
but mice on the LowMg-HFD gained significantly less weight
than those on the normal Mg2+(NormMg)-HFD (47.00 ±
1.53 g vs 38.62 ± 1.51 g in mice given a NormMg-HFD and
LowMg-HFD, respectively, p < 0.05, Fig. 1a,b). The lower
body weight of the LowMg-HFD group could not be ex-
plained by differences in dietary intake, as shown by similar
food intake and faeces production between the two HFD
groups (Fig. 1c,d). There was also no difference in water in-
take or urinary volume between the HFD groups (Fig. 1e,f).
Hypomagnesaemia was detected in both the LowMg groups,
but was significantly more pronounced in mice that were con-
comitantly fed an HFD (Fig. 1g).
Reduced diet-induced obesity in Mg2+-deficient mice is ac-
companied by improved insulin sensitivityTo explore glucose
metabolism in more detail, beta cell function and insulin sen-
sitivity were determined by IPGTT and IPITT. In the IPGTT
(a measure for beta cell dysfunction and insulin resistance),
glucose clearance was reduced in both HFD groups (Fig. 2a).
Glucose clearance was not significantly different between
NormMg-HFD-fed mice and LowMg-HFD-fed mice (2.58
± 0.08 vs 2.26 ± 0.13 mol/l × min in NormMg-HFD- and
LowMg-HFD-fed mice, respectively, p = 0.07, Fig. 2c).
LowMg-HFD-fed mice required significantly less insulin than
NormMg-HFD-fed mice to clear the glucose, consistent with
LowMg-HFD-fed mice being more insulin sensitive (Fig. 2b).
Fasting blood glucose and insulin concentrations were signi-
ficantly increased in the HFD-fedmice, in accordancewith the
increased body weight (Fig. 2d,e). Compared with the
NormMg-HFD-fed mice, fasting blood glucose was lower in
the LowMg-HFD-fed mice (Fig. 2d). The effect of dietary
Mg2+ on fasting insulin was not statistically significant
(Fig. 2e, two-way ANOVA for dietary Mg2+ effect, p = 0.07).
Both HFD-fed groups demonstrated increased insulin re-
sistance in the ITT compared with their respective controls
(Fig. 2f,g). Low dietary Mg2+ content resulted in a significant-
ly lower AUC of the ITT (Fig. 2g, two-way ANOVA for
dietary Mg2+ effect p < 0.05). In the LowMg-HFD group
compared with the NormMg-HFD-fed mice, the AUC of the
ITT was not significantly different (0.91 ± 0.05 vs 0.72 ±
0.05 mol/l × min in NormMg-HFD-fed and LowMg-HFD-
fed mice, respectively, Tukey’s test p = 0.07, Fig. 2f,g).
Insulin resistance is often accompanied by hyperlipidae-
mia, in particular, high triacylglycerol and NEFA levels. As
expected, the HFD-fed mice had higher serum triacylglycerol
and NEFA levels than LFD-fed mice (Fig. 2h,i). Interestingly,
despite their lower body weight and increased insulin sensi-
tivity, LowMg-HFD-fed mice also had high serum triacyl-
glycerol and NEFA (Fig. 2h,i). In contrast, serum leptin levels
correlated with bodyweight; hence, reduced leptin levels were
observed in the LowMg-HFD-fed mice compared with
NormMg-HFD-fed mice (Fig. 2j). No difference between
the two HFD groups was observed in serum adiponectin and
cholesterol (ESM Fig. 1a,b).
Mg2+ deficiency prevents diet-induced hepatic lipid storage
Liver function is often impaired in type 2 diabetes as a conse-
quence of insulin resistance and hepatic steatosis [28].
Feeding mice a NormMg-HFD resulted in a significantly
Diabetologia (2018) 61:2030–2042 2033
heavier liver. However, this effect was abrogated in mice fed a
LowMg-HFD (Fig. 3a). In Mg2+-deficient mice, the HFD did
not increase liver triacylglycerol content (Fig. 3b). In line with
the triacylglycerol measurements, H&E and Oil Red O stai-
ning showed reduced hepatic lipid accumulation in the Mg2+-
deficient HFD-fed mice (Fig. 3c,d, respectively). Hepatic
mRNA expression of Cd36, a long-chain fatty acid transpor-
ter, was reduced in the LowMg-HFD-fed mice compared with
the NormMg-HFD-fed mice (ESM Fig. 2a). Low dietary
Mg2+ increased hepatic mRNA expression of sterol regulatory
element-binding protein 1c (Srebp1c), which is involved in
cholesterol and fatty acid metabolism, and phosphoenolpy-
ruvate carboxykinase 1 (Pepck1), essential for gluconeogene-
sis, glyceroneogenesis and fatty acid re-esterification (ESM
Fig. 2b,c, two-way ANOVA for dietary Mg2+ effect p <
0.05). No differences were observed between the two HFD-
fed groups in the expression of key genes involved in hepatic
glycolysis, ketogenesis and β oxidation (ESM Fig. 2d–l).
Reduced adipose tissue mass in Mg2+-deficient HFD-fed mice
is associated with increased mRNA expression of lipolysis
genes Our results show that mice fed a LowMg-HFD diet
exhibit reduced body weight and high triacylglycerol levels
compared with their NormMg-HFD-fed littermates.
Interestingly, the LowMg-HFD group had decreased mass of
epididymal and inguinal white adipose tissue (eWAT and
iWAT, respectively) (Fig. 4a,b), which may point towards de-
fective lipid handling in white adipose tissue (WAT). The
HFD increased adipocyte size (Fig. 4c,d), but no significant
difference was observed between the two HFD groups (Fig.
a
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Fig. 1 Low dietary Mg2+ intake
reduces diet-induced obesity in
mice. Adult mice (n = 12mice per
group, n = 11 mice for the
LowMg-HFD group) were fed a
diet with either an LFD or an
HFD, combined with a normal or
low Mg2+ concentration, for
17 weeks. (a) Body weight,
determined twice weekly. Arrows
indicate experimental
interventions: metabolic cage
(MC), ITT and GTT. (b) The
body weight of mice at week 17
(the end of the experiment). (c)
Food intake, (d) total faeces
weight, (e) water intake (two-way
ANOVA for dietary fat effect p <
0.05) and (f) urine production
determined over a period of 24 h,
using metabolic cages, at week
16. (g) Serum Mg2+ levels at
death. NormMg-LFD (white
circles), LowMg-LFD (grey
circles), NormMg-HFD (white
squares), LowMg-HFD (grey
squares). Data are mean ± SEM.
Depending on the absence or
presence of a significant
interaction effect between dietary
fat and Mg2+ content, either a
two-way ANOVA (Tukey’s
multiple comparison test) or an
unpaired multiple t test (Holm–
Sidak multiple comparison test)
approach, respectively, was used
to determine statistical
significance. *p < 0.05 for the
comparisons shown
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4c,d). Nevertheless, quantitative PCR showed that mRNA
expression of Srebp1c, Pepck1 and genes involved in β oxi-
dation was increased in the eWAT of the LowMg-HFD group
compared with the NormMg-HFD group (ESM Fig. 3a–f).
To determine the consequences of low Mg2+ on lipid me-
tabolism, we performed RNA sequencing on eWAT. A prin-
cipal component analysis using the log2 transformed expres-
sion values shows that the samples from both LFD groups
cluster closely together, indicating the absence of a strong
Mg2+ effect, whereas there is a clear separation of NormMg-
HFD vs LowMg-HFD gene expression profiles (Fig. 4e). To
investigate the effect of Mg2+ on specific biological pathways,
the fold changes for groups of genes belonging to the same
gene ontology (GO) were analysed. GO term analysis indica-
ted that processes associated with adiposity (e.g. inflamma-
tion) were downregulated in LowMg-HFD-fed vs NormMg-
HFD-fed mice, in accordance with decreased adipose tissue
mass (ESM Table 2). Interestingly, despite the increased insu-
lin sensitivity of the LowMg-HFD-fed mice, several key
genes involved in the triacylglycerol catabolism pathway
(lipolysis) were upregulated in the LowMg-HFD vs the
NormMg-HFD group, which may explain the reduced lipid
storage as well as the high serum NEFA levels (Fig. 4f). A
modest increase in acyl-CoA dehydrogenase dependent β
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Fig. 2 Reduced diet-induced
obesity in Mg2+-deficient mice is
accompanied by high
triacylglycerol levels and
improved insulin sensitivity. (a)
Glucose clearance determined by
IPGTT at week 15. (b) Serum
insulin measured at 0, 15 and
120 mins of the GTT. (c) AUC
determined between 0 and
120 min. (d) Fasting blood
glucose and (e) serum insulin
measured during the GTT. (f)
Blood glucose measured during
an IPITT at week 14 (n = 9 mice
per group, n = 12 for the
NormMg-LFD. (g) AUC
determined between 0 and
120 min (two-way ANOVA for
dietary Mg2+ effect, p < 0.05).
Non-fasted serum (h)
triacylglycerol, (i) NEFA and (j)
leptin concentrations at death
(n = 12 mice for both LFD
groups, n = 11 mice for both HFD
groups). NormMg-LFD (white
circles), LowMg-LFD (grey
circles), NormMg-HFD (white
squares), LowMg-HFD (grey
squares). Data are mean ± SEM.
Depending on the absence or
presence of a significant
interaction effect between dietary
fat and Mg2+ content, either a
two-way ANOVA (Tukey’s
multiple comparison test) or an
unpaired multiple t test (Holm–
Sidak multiple comparison test)
approach, respectively, was used
to determine statistical
significance. *p < 0.05 for the
comparisons shown
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oxidation was observed in the LowMg-HFD-fed mice vs the
NormMg-HFD-fed mice (Fig. 4g). The metabolic effects of
Mg2+ in eWAT appear to be specific to lipid homeostasis, as
there was no clear effect on glycolysis (ESM Fig. 3g).
Although serum cholesterol levels were not different between
the experimental groups, cholesterol biosynthesis was greatly
reduced in the LowMg-HFD-fed vs the NormMg-HFD-fed
mice (ESM Fig. 3h, ESM Table 2).
To investigate whether hypomagnesaemia has a direct ef-
fect on lipolysis in eWAT, we examined the effect of Mg2+ on
lipolysis in differentiated 3 T3-L1 cells in vitro. Unstimulated
lipolysis was not different at 0 or 1 mmol/l Mg2+, indicating
that Mg2+ deficiency does not directly induce lipolysis in
adipocytes (ESM Fig. 4a).
mRNA expression of the β3-adrenergic receptor is increased
in LowMg-HFD mice β3-Adrenergic receptors (ADRB3) are
essential regulators of lipid metabolism, increasing brown
adipose tissue (BAT) activity and reducing WAT lipid storage
via activation of lipolysis [29–32]. We therefore explored
whether enhanced β-adrenergic signalling could explain the
high triacylglycerol levels, increased lipolysis and reduced
body weight of Mg2+-deficient HFD-fed mice. Expression of
Adrb3 was significantly increased by 2.5-fold in the eWAT of
LowMg-HFD-fed compared with NormMg-HFD-fed mice
(Fig. 5a). Additionally, both HFD-fed groups showed elevated
mRNA expression of Adrb3 in BAT, but this upregulation was
more pronounced in the LowMg-HFD group (Fig. 5b). To
determine whether this was the result of enhanced adrenaline
(epinephrine) release, serum levels of the dopamine metabo-
lite 3-methoxytyramine and the adrenaline metabolite
normetanephrine were measured. However, no significant in-
crease was observed (Fig. 5c and ESM Fig. 5a). mRNA ex-
pression of the lipolysis genes adipose triacylglycerol lipase
(Atgl), hormone-sensitive lipase (Hsl) and monoglyceride li-
pase (Mgll) was significantly increased in eWAT of Mg2+-
deficient HFD-fed mice compared with the NormMg-HFD
group (Fig. 5d–f).
Expression of Ucp1 in BAT, which is essential for non-
shivering thermogenesis, was upregulated in NormMg-HFD-
fed mice compared with NormMg-LFD-fed mice (Fig. 5g). In
line with increased β3-adrenergic signalling, Ucp1 expression
was further increased in BATof LowMg-HFD-fed mice. BAT
thermogenesis is strongly regulated by fatty acid availability
[33]. Indeed, genes involved in NEFA metabolism of BATare
upregulated (Fig. 5h–j) (Atgl, Cpt1-m and Acadl). In contrast,
mRNA levels of glucose transporters 1 and 4 (Glut1/4) in
BAT were unchanged in LowMg-HFD-fed compared with
NormMg-HFD-fed mice (ESM Fig. 5b,c). mRNA expression
of the fatty acid transporter Cd36 and of the important meta-
bolic transcription factors peroxisome proliferator-activated
receptor alpha (Pparα) and gamma (Pparγ) remained un-
changed in BAT between the NormMg-HFD-fed and
LowMg-HFD-fed mice (ESM Fig. 5d–f).
LowMg-HFD-fed mice have increased body temperature but
equal energy expenditure To investigate the energy metabo-
lism inMg2+-deficient HFD-fed mice, the dietary intervention
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Sidak multiple comparison test) approach was used, respectively, to de-
termine statistical significance. (d) Representative images of H&E stained
eWAT. Scale bars, 100 μm. (e) Principal component (PC) analysis of
RNA sequencing on eWAT. NormMg-LFD (white circles, n = 4),
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acyl-CoA dehydrogenase’; and ‘positive regulation of fatty acid β-oxida-
tion’. Gene expression changes are presented as log2 fold change with the
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for the comparisons shown
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study was repeated with respiratory cages. Respiration, body
temperature and activity were measured at week 8, which was
when the weight differences developed in our first experiment.
In line with the previous experiment, no differences were ob-
served in food and water intake between the two HFD-fed
groups (ESM Fig. 6a–d); and the Mg2+-deficient HFD-fed
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Fig. 5 mRNA expression of the β3-adrenergic receptor is increased in
eWATof LowMg-HFD-fedmice. Relative mRNA expression ofAdrb3 in
(a) eWAT and (b) BAT, normalised to Gapdh expression, relative to
NormMg-LFD. (c) Serum 3-methoxytyramine concentration at death
(17 weeks, n = 12 mice in the NormMg-HFD group, n = 11 in the
LowMg-HFD group). eWAT mRNA expression of genes essential for
lipolysis, (d) Hsl, (e) Atgl and (f)Mgll, normalised to Gapdh expression,
relative to NormMg-LFD (n = 12 mice per group, n = 11 mice for the
LowMg-HFD group). BAT mRNA expression of (g) Ucp1 and genes
involved in fatty acid metabolism, (h) Cpt1-m, (i) Atgl and (j) Acadl,
normalised to Gapdh expression, relative to NormMg-LFD (n = 10 mice
for both LFD groups, n = 11 mice for both HFD groups). NormMg-LFD
(white circles), LowMg-LFD (grey circles), NormMg-HFD (white
squares), LowMg-HFD (grey squares). Data are mean ± SEM.
Depending on the absence or presence of a significant interaction effect
between dietary fat and Mg2+ content, either a two-way ANOVA
(Tukey’s multiple comparison test) or an unpaired multiple t test
(Holm–Sidak multiple comparison test) approach, respectively, was used
to determine statistical significance. Statistical significance in 3-
methoxytyramine levels was assessed using a t test. *p < 0.05 for the
comparisons shown
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mice had reduced body weight compared with the NormMg-
HFD-fed mice (Fig. 6a). Lean body mass was not different
between the two HFD groups, indicating that the weight dif-
ference depends on adipose tissue mass (Fig. 6b). As with our
previous experiment, the HFD caused a reduction in serum
Mg2+ levels (Fig. 6c). A significant increase was observed in
serum triacylglycerol when the animals were killed (after
9 weeks) in the LowMg-HFD group compared with the
NormMg-HFD group (Fig. 6d). Low dietary Mg2+-fed mice
had decreased non-fasted serum glucose (Fig. 6e; two-way
ANOVA for dietary Mg2+ effect p < 0.05), while the difference
between the two HFD-fed groups was not significant
(NormMg-HFD vs LowMg-HFD, Tukey’s test p = 0.07).
Hypomagnesaemia and HFD decreased core body temperature
(Fig. 6f). In contrast, the body temperature of LowMg-HFD-fed
mice was higher than NormMg-HFD-fed mice (Fig. 6f; 35.8 ±
0.1 vs 36.4 ± 0.2°C in NormMg-HFD and LowMg-HFD, p <
0.05), in line with increased BATactivity. Moreover, mice fed a
Mg2+-deficient diet showed increased locomotor activity (ESM
Fig. 6e,f; two-way ANOVA for dietary Mg2+ effect p < 0.05).
However, energy expenditure was not different between the two
HFD-fed groups (Fig. 6g,h). In both HFD groups, the respira-
tory exchange ratio (RER) was approximately 0.7, indicating
that fatty acids are the main energy source (Fig. 6i,j).
Interestingly, in the LFD groups, hypomagnesaemia resulted
in a reduction of the RER (Fig. 6i,j), suggesting an increased
use of fatty acids as an energy substrate over glucose. However,
this reduction was not statistically significant (Fig. 6j; 0.82 ±
0.01 vs 0.79 ± 0.01 average RER in NormMg-LFD and
LowMg-LFD, respectively; p = 0.10).
Discussion
Hypomagnesaemia has been repeatedly reported in type 2
diabetes and the metabolic syndrome [1, 2, 14], but the role
of Mg2+ in lipid metabolism has been largely overlooked.
Here, we demonstrate that low dietary Mg2+ intake amelio-
rates HFD-induced obesity. The lower body weight results in
beneficial metabolic effects including improved insulin sensi-
tivity, reduced hepatic steatosis and lower WAT inflammation.
Nevertheless, serum triacylglycerol and NEFA concentrations
were increased in the lowMg2+ HFD group, corresponding to
increased eWAT mRNA expression of lipolysis genes. These
findings establish Mg2+ as an important regulator of body
weight and lipid metabolism.
In this study, a Mg2+-deficient diet ameliorated HFD-
induced weight gain in mice. This was the result of reduced
adiposity, because lean body mass was similar between the two
HFD groups and both eWAT and iWAT weight were lower in
mice fed a LowMg-HFD compared with a NormMg-HFD. The
reduced body weight was associated with favourable metabolic
effects. IPGTT, IPITT and fasting glucose levels indicated
enhanced insulin sensitivity. Moreover, the reduced body
weight of the LowMg-HFD mice led to a complete absence
of hepatic steatosis and RNA sequencing of the eWAT demon-
strated downregulation of pro-inflammatory pathways. Despite
these beneficial effects, blood lipid levels remained high. In line
with our data, others have demonstrated that low dietary Mg2+
intake reduced body weight in several rat models of Mg2+ de-
ficiency [34–37]. However, these studies did not address the
underlying cause or investigate the effects on lipid metabolism.
Our animal data is strengthened by the results of Chubanov
et al [17] where severe hypomagnesaemia via Trpm6 knockout
also resulted in a catabolic phenotype and improved insulin
sensitivity [17]. The catabolic phenotype of Mg2+-deficient
mice leads to hyperlipidaemia, which has considerable adverse
effects in individuals with type 2 diabetes [38, 39].
Nevertheless, the low Mg2+ HFD does not completely mimic
the human situation because the hypomagnesaemia induced in
mice is more severe [1]. Moreover, an unhealthy human diet
consists of both high fat and sugar, whereas the HFD in mice
purely depends on palm oil. Indeed, Mg2+-deficiency in high-
fructose diets has adversely affected insulin sensitivity and lipid
homeostasis in rats. This shows the considerable differences in
the role of Mg2+ in the metabolism of lipids vs carbohydrates
[40, 41]. Future studies should investigate the role of Mg2+ in
combined fat and sugar diets. These differences may explain
why, in humans, higher oralMg2+ intake andMg2+ supplemen-
tation have beneficial effects on metabolic variables, which
apparently contrasts with our animal data [18–20].
In our study, the reduced WAT mass of LowMg-HFD-fed
mice was associated with enhanced lipolysis gene expression,
causing high serum NEFA and triacylglycerol levels. These
findings suggest that LowMg-HFD-fed mice depend more on
mitochondrial β-oxidation, rather than glycolysis, for energy
production. However, our energy metabolism experiments
demonstrated neither differences in energy expenditure nor
in RER between the NormMg-HFD and LowMg-HFD
groups. It should be noted, however, that both HFD groups
mainly depend on lipids for energy metabolism, masking po-
tential RER differences between these groups. Moreover,
despite equal energy expenditure, the NormMg-HFD-fed
mice are considerably heavier than LowMg-HFD-fed mice
and therefore have a higher energy demand. Several studies
have discussed the considerable difficulties associated with
the interpretation of energy expenditure data and emphasised
that body weight differences complicate interpretation [42,
43]. Increased thermogenesis may explain why energy expen-
diture does not differ between LowMg-HFD-fed and the
heavier NormMg-HFD-fed mice. Although the effects are
modest, the LowMg-HFD-fed mice had a significantly higher
body temperature and increased Ucp1 expression in BAT, in-
dicative of higher thermogenesis. Cold-exposure studies are
necessary to further investigate the role of Mg2+ status in BAT
activation, WAT browning and thermogenesis.
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Fig. 6 LowMg-HFD-fed mice have increased body temperature but
equal energy expenditure. To study energy expenditure, a replication
animal study was performed for a duration of 9 weeks. (a) Body weight
and (b) lean body weight of the animals (n = 10 mice per group, n = 9
mice in the LowMg-LFD group) at death (9 weeks). Non-fasted serum (c)
Mg2+, (d) triacylglycerol and (e) glucose concentrations at death (glucose
at 9 weeks, two-way ANOVA for dietaryMg2+ effect p < 0.05; NormMg-
HFD vs LowMg-HFD Tukey’s test p = 0.07). (f) Body temperature mea-
sured by rectal probe after 8 weeks of dietary intervention. Respiratory
metabolic cages were used to determine energy expenditure and RER. (g)
Energy expenditure averaged per hour, measured after 8 weeks of dietary
intervention and corrected for lean weight, (h) from which the AUC is
calculated. NormMg-LFD (white circles, n = 10), LowMg-LFD (grey
circles, n = 9), NormMg-HFD (white squares, n = 10), LowMg-HFD
(grey squares, n = 10). (i) RER averaged per hour, measured after 8 weeks
of dietary intervention. RER is determined by dividing the CO2 produc-
tion by the O2 intake. (j) Average RER over the entire duration of the
measurement (from 18:30 to 09:30 h). NormMg-LFD (white circles),
LowMg-LFD (grey circles), NormMg-HFD (white squares), LowMg-
HFD (grey squares). Data are mean ± SEM. Depending on the absence
or presence of a significant interaction effect between dietary fat and
Mg2+ content, either a two-way ANOVA (Tukey’s multiple comparison
test) or an unpaired multiple t test (Holm–Sidak multiple comparison test)
approach, respectively, was used to determine statistical significance. *p
< 0.05 for the comparisons shown
2040 Diabetologia (2018) 61:2030–2042
The increased lipolysis and brown adipose tissue acti-
vity were associated with higher β3-adrenergic receptor
expression in eWAT and BAT of LowMg-HFD-fed mice.
β3-receptor knockout mice have increased lipid stores and
impaired WAT browning [44, 45]. Activation of the β3-
adrenergic receptors in mice using agonist CL316243 de-
creases adipose tissue mass, improves insulin sensitivity,
increases uncoupling protein-1 (UCP1)-dependent thermo-
genesis and activates a cycle of concomitant lipolysis and
de novo lipogenesis [46, 47]. Interestingly, this is exactly
the phenotype that was observed in the LowMg-HFD-fed
mice, although to a lesser extent. A link between Mg2+, β-
adrenergic signalling and lipolysis is not without prece-
dent. Use of β-adrenergic agonists, which stimulate lipol-
ysis, have been associated with decreased blood Mg2+
levels [1, 48, 49]. Mg2+ has also been shown to reduce
catecholamine release from the adrenal medulla [50] and
Mg2+ deficiency is associated with higher urinary levels of
adrenaline and noradrenaline (norepinephrine) [37].
Moreover, Mg2+ supplementation has been suggested to
regulate lipolysis, as it prevents hyperlipidaemia in diabe-
tic rats and reduces serum triacylglycerol levels in indivi-
duals with type 2 diabetes [20, 51]. Further research is
required to determine exactly how hypomagnesaemia
increases β-adrenergic signalling and how β-adrenergic
signalling can induce hypomagnesaemia.
A strength of this study is that the model used to induce
type 2 diabetes and low dietary Mg2+ intake closely resembles
the human situation. The Western diet contains high amounts
of processed foods consisting of high energy and low Mg2+.
Moreover, the extensive phenotyping of the animals in this
study provides new avenues for research into the pivotal role
of Mg2+ in metabolism. The data obtained in this study are
robust, as a replicate animal experiment was performed in a
separate institution, confirming our results.
Our study has limitations. First, because of the large weight
differences induced by the Mg2+ deficient diet, it is difficult to
specifically attribute the metabolic changes of themice to their
lower body weight or their Mg2+ deficiency. In addition, our
study design did not allow us to study in more depth the
contribution of disturbed β-adrenergic signalling to the diffe-
rences in body weight, eWAT lipolysis, BAT activity and hy-
perlipidaemia. Although our data and previous studies support
a role for Mg2+ in β-adrenergic signalling [37, 50], further
studies are required to establish the exact role of Mg2+ in
catecholamine secretion and signalling.
In conclusion, our results demonstrate that hypo-
magnesaemia in mice prevents HFD-induced weight gain
by enhanced BAT activity and increased eWAT lipolysis
gene expression. Consequently, this led to improved insu-
lin sensitivity and absent hepatic steatosis. These results
underline the pivotal function of Mg2+ in maintaining a
healthy energy metabolism.
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